semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Invasive Breast Cancer Patients must be female and 18 years of age or older Patients must have a clinical T1, T2, or T3 tumor size Patients must have a histopathologic tissue diagnosis of breast cancer by a core-type of breast biopsy Patients must have had biopsy-proven involvement of the axillary lymph nodes at initial presentation based on fine needle aspiration (FNA) cytology, core/Tru-cut biopsy, or pre-treatment SLN biopsy that will require an axillary lymph node dissection to be performed at the time of the definitive breast cancer surgery Patients will have had to undergone preoperative neoadjuvant systemic chemotherapy Patients may be candidates for either lumpectomy or mastectomy Patients may have a history of a previously treated metachronous contralateral breast cancer in the past Patients may have synchronous bilateral breast cancer  Patients must not be pregnant (The absence of pregnancy must be documented by any one of the following: negative serum pregnancy test, the history of surgical sterilization, or the absence of menstruation for at least six months prior to enrollment in the study) Patients may not have a history of previous treated ipsilateral breast cancer in the past
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Schizophrenia Schizoaffective Disorder Bipolar Disorder Obesity Metabolic Syndrome Age 18-65; 2. DSM-IV-TR diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder; 3. Patients who, in the clinical judgment of the investigator, may benefit from a switch to olanzapine; 4. Females must be of non-child bearing potential (i.e., surgically sterilized, or at least one year post-menopausal) or on an appropriate dose of oral/depot contraceptives or using barrier protection and not breast-feeding. Females must have a urine pregnancy test at screening; 5. Willingness and ability to take medications nightly at 10:00 p.m.; and 6. The subject or his/her legal representative must provide informed, written consent  Females who are pregnant or lactating; 2. Concurrent participation or participation within the prior 30 days in any study involving investigational medications; 3. Current (within the prior 30 days) diagnosis of substance abuse or dependence; 4. Use of olanzapine within the prior three months; 5. History of allergy or intolerable side-effects to olanzapine in the past; 6. History of significant head trauma, defined as head trauma resulting in loss of consciousness for more than five minutes and/or neurological or cognitive sequelae; 7. Evidence of any clinically relevant disease (e.g., renal or hepatic impairment, significant coronary artery disease, cerebrovascular disease, or cancer) or any clinical finding that in the opinion of the investigator could potentially be negatively affected by study participation or that could potentially affect study participation is criterion for from the study; 8. Use of fluvoxamine, nifedipine, or warfarin for 30 days prior to Baseline Visit
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed breast cancer, including the following histologic subtypes Invasive ductal carcinoma Medullary ductal carcinoma Papillary ductal carcinoma Colloid (mucinous) ductal carcinoma Tubular ductal carcinoma The following histologic subtypes are not allowed Invasive lobular carcinoma Extensive lobular carcinoma in situ Ductal carcinoma in situ (DCIS)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer All patients who present to M. D. Anderson for a stereotactic guided 9 gauge vacuum-assisted breast biopsy and undergo stereotactic biopsy with biopsy clip deployment would be considered for the study  If patient refuses biopsy or the biopsy is cancelled they will not be eligible No biopsy clip is seen on the immediate postprocedure mammogram and no additional clip will be deployed Pregnant women are excluded from the study Patients who have had a previous biopsy or surgery in the same (ipsilateral) breast are excluded from the study
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-60.0,  Breast Cancer Meets 1 of the following Current or prior diagnosis of lobular carcinoma in situ (LCIS) of the breast, including any of the following cases Pure LCIS LCIS with subsequent development of invasive breast cancer of any morphological subtype LCIS presenting as an incidental finding together with invasive breast cancer of any morphological subtype Control participant matched for age and ethnicity to each LCIS patient Not affected by LCIS No history of ductal carcinoma in situ of the breast No breast cancer No relative (up to 2nd degree) who has been affected by breast cancer
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer Women with Estrogen Receptor (ER), Progesterone Receptor (PR),and HER2 negative invasive breast cancer confirmed on core biopsy.(Note: HER2 negative by FISH preferred; HER2 0 or 1+ by IHC acceptable) Primary tumor size 2cm or greater by physical exam or radiographic measurements.(Note: Locally advanced T4 or inflammatory breast cancer is eligible.) Assessment of pre-treatment axillary lymph nodal status (Note: FNA biopsy if palpable or sentinel lymph node biopsy (SLNB) if not palpable preferred; clinical exam acceptable.) Absolute neutrophil count > 1500 mm3 and platelet count > 100,000 mm3 Normal myocardial left ventricular function Serum creatinine < 2.0 mg/dl Total bilirubin and AST < 3X upper limits normal  Recurrent or metastatic breast cancer findings (Note: If oncologically felt to be a second breast primary, patient eligible for this protocol) Another active cancer present Medical contraindications to chemotherapy or surgery First trimester pregnancy Breast feeding
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Carcinoma of the Breast Histologically confirmed invasive carcinoma of the breast Tumors must be less than or equal to 3cm in greatest dimension Must have node-negative breast cancer according to teh AJCC 7th edition ER/PR determination is required. ER and PR-assays should be performed by immunohistochemical methods HER-2 positive: IHC 3+ or FISH >2 Bilateral breast cancers that individually meet are allowed Patients should have tumor tissue available, and a tissue block of sufficient size to make 15 slides must be sent to DFCI for testing Less than or equal to 84 days from mastectomy or from axillary dissection or sentinel node biopsy if the patient's most extensive breast surgery was a breast-sparing procedure All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy), with either a sentinel node biopsy or axillary dissection  Pregnant or nursing women Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes History of prior chemotherapy in past 5 years History of prior trastuzumab therapy Active, unresolved infection Prior history of any other malignancy in the past 5 years, except for early stage tumors of the skin or cervix treated with curative intent Sensitivity to benzyl alcohol Grade 2 or greater neuropathy per NCI's CTCAv3.0. (Exception: Any chronic neurologic disorder will be looked at on a case-by-case basis by the study chair) Active cardiac disease as outlined in protocol
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Postmenopausal women defined as: aged >/= 50 years with amenorrhea for at least 12 months or aged < 50 years with 6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) level within postmenopausal range (> 40 mIU/ml) or having undergone bilateral oophorectomy Histologically or cytologically confirmed breast cancer Metastatic breast cancer (Stage IV according to UICC Union Internationale Contre Cancer Version 6) Progesterone receptor-positive tumors Patients must be considered candidates for endocrine therapy (no other therapies for breast cancer are required) Disease progression after first-line endocrine therapy for advanced breast cancer (i.e. with tumor remission or stabilization lasting at least 3 months under endocrine therapy) At least one measurable or non-measurable tumor lesion (according to criteria) WHO Performance status 1  Presence of any of the following conditions life-threatening metastatic visceral disease (extensive hepatic involvement) any metastases to the central nervous system (CNS) pulmonary lymphangitic metastases involving more than 50% of the lung More than one prior endocrine treatment for advanced breast cancer Previous combination of endocrine treatment with any other type of treatment (except chemotherapy), or previous sequential endocrine treatments (if there was disease progression between treatments) are not permitted in this trial Patients with breast cancer HER-2 positive or with unknown HER-2 status are not eligible Malignancies or history of prior malignancy other than carcinoma in situ of the cervix or uterus, or basal and squamous cell carcinoma of the skin Intake of CYP3A4 inhibitors less than 2 weeks before start of study treatment A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Breast Cancer Histologically confirmed stage I breast cancer Size ≤ 20 mm (by ultrasound), N0, any quadrant Hormone receptor status not specified  Distant metastases Inflammatory breast cancer Lobular in situ disease Invasive cancer or ductal carcinoma in situ Nonepithelial disease or sarcoma Multicentric disease Lymphatic embolism Margins of safety unknown or positive (in situ or invasive) Preoperative mammography showing diffuse microcalcification Female
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Breast Cancer Patients with biopsy-proven DCIS, mammographic and CE-MRI evidence of DCIS measuring great then equal to 4cm, and a desire to receive breast conserving therapy, will be considered for participation in this study Patient history, physical examination findings, and demographics (sex, age, height, weight, bra size, etc.) will be performed and documented. for Initial Registration (all patients cohorts): All cohorts Signed informed consent and HIPAA documents Female sex Age great then equal to 40 years Localized ductal carcinoma in situ Clinically and/or histologically negative axillary lymph nodes No imaging or clinical findings suggestive of invasive carcinoma. Cohort 1 (Immediate IORT group) Localized DCIS measuring less then equal to 4 cm on preoperative imaging Cohort 2 (Delayed IORT group)  Male sex Age less than 40 DCIS associated with any evidence of microinvasion or invasive carcinoma on pre-operative imaging or core biopsy of the breast or axillary nodes DCIS that is multicentric in the ipsilateral breast. Multicentricity will be defined at 2 or more lesions separated by more than 3 cm in the same breast Non-epithelial breast malignancies such as sarcoma or lymphoma DCIS associated with diffuse suspicious or indeterminate microcalcifications Pregnancy or lactation Collagen vascular diseases, including Systemic lupus erythematosus, Systemic sclerosis (scleroderma), CREST Syndrome (calcinosis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia, and the presence of anticentromere antibodies), polymyositis, dermatomyositis with a CPK level above normal or with an active skin rash, inclusion-body myositis, or amyloidosis Serious psychiatric or addictive disorders
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cancer of the Breast Female, 18-100 years old Not pregnant or breastfeeding Pre-study radiologic documentation of size ≤ 5 cm unicentric, unilateral suspicious mass or calcification classification ≥ IV location of abnormality > 1 cm from skin Ductal or Infiltrating Ductal Carcinoma Grade I-III on final pathology  Patient < 18 y/o or > 100 y/o Pregnant or breastfeeding Male Breast implants Multicentric disease or bilateral disease Lesions > 5 cm in diameter Lesions < 1.0 cm from the skin Previous prior radiation to the breast Need for mastectomy Diffuse microcalcifications (as determined by the Investigator)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Breast Cancer Female, 18 to 90 years of age Non-pregnant, not breastfeeding Pre-study documentation of Size ≤1.5 cm cancer successfully removed by US-guided IVEB within 30 days of registration Uni-centricity, unilateral cancer by radiology (mammogram and MRI) Location of abnormality > 1 cm from the skin Ductal Carcinoma, Invasive (Grade I-III) or In-Situ No palpable axillary or supraclavicular lymph nodes Good general health Zubrod Performance Status of 0, 1, or 2  Subjects less than 18 years of age or greater than 90 years of age Pregnant or breastfeeding Male Prior Breast Biopsy affected breast Breast implants Multicentric disease, bilateral disease Residual disease after IVEB of > 1cm on MRI Lesions > 1.5 cm in diameter Lesions < 1 cm from skin surface Previous radiation therapy to the breast